Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial.
Saved in:
| Title: | Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. |
|---|---|
| Authors: | Beernink JM; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Mosterd CM; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Scholtes RA; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Caldwell-McGee A; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Casillas D; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Driscoll L; Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA., Greasley PJ; Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Mölndal, Sweden., Karlsson C; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Hammarstedt A; Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Sridhar VS; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Muskiet MHA; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands., Laverman GD; Department of Internal Medicine, ZGT Hospital, Almelo and Hengelo, The Netherlands., Cherney DZI; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada., Bjornstad P; Division of Metabolism, Endocrinology and Metabolism, Department of Medicine, University of Washington, Seattle, Washington, USA., van Raalte DH; Department of Endocrinology and Metabolism, Amsterdam University Medical Centers, Location VUMC, Diabetes Center, Amsterdam, The Netherlands.; Amsterdam Cardiovascular Sciences, VU University, Amsterdam, The Netherlands., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. |
| Source: | Diabetes, obesity & metabolism [Diabetes Obes Metab] 2025 Aug; Vol. 27 (8), pp. 4415-4426. Date of Electronic Publication: 2025 May 30. |
| Publication Type: | Clinical Trial, Phase IV; Journal Article; Multicenter Study |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
